Evans Denise, Menezes Colin, Mahomed Kay, Macdonald Philippa, Untiedt Sanlie, Levin Leon, Jaffray Imogen, Bhana Nainisha, Firnhaber Cindy, Maskew Mhairi
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
AIDS Res Hum Retroviruses. 2013 Jun;29(6):892-900. doi: 10.1089/AID.2012.0215. Epub 2013 Feb 25.
There is little evidence comparing treatment outcomes between adolescents and other age groups, particularly in resource-limited settings. A retrospective analysis of data from seven HIV clinics across urban Gauteng (n=5) and rural Mpumalanga (n=2), South Africa was conducted. The analysis compared HIV-positive antiretroviral treatment (ART)-naive young adolescents (10-14 years), older adolescents (15-19), and young adults (20-24 years) to adults (≥25 years) initiated onto standard first-line ART between April 2004 and August 2010. Log-binomial regression was used to estimate relative risk (RR) of failure to suppress viral load (≥400 copies/ml) or failure to achieve an adequate CD4 response at 6 or 12 months. The effect of age group on virological failure, mortality, and loss to follow-up (LTFU; ≥90 days since scheduled visit date) was estimated using Cox proportional hazards models. Of 42,427 patients initiating ART, 310 (0.7%) were young adolescents, 342 (0.8%) were older adolescents, and 1599 (3.8%) were young adults. Adolescents were similar to adults in terms of proportion male, baseline CD4 count, hemoglobin, and TB. Compared to adults, both older adolescents (6 months RR 1.75 95% CI 1.25-2.47) and young adults (6 months RR 1.33 95% CI 1.10-1.60 and 12 months RR 1.64 95% CI 1.23-2.19) were more likely to have an unsuppressed viral load and were more likely to fail virologically (HR 2.90 95% CI 1.74-4.86; HR 2.94 95% CI 1.63-5.31). Among those that died or were LTFU, the median time from ART initiation until death or LTFU was 4.7 months (IQR 1.5-13.2) and 10.9 months (IQR 5.0-22.7), respectively. There was no difference in risk of mortality by age category, compared to adults. Young adolescents were less likely to be LTFU at any time period after ART initiation (HR 0.43 95% CI 0.26-0.69) whereas older adolescents and young adults were more likely to be LTFU after ART initiation (HR 1.78 95% CI 1.34-2.36; HR 1.63 95% CI 1.41-1.89) compared to adults. HIV-infected adolescents and young adults between 15 and 24 years have poorer ART treatment outcomes in terms of virological response, LTFU, and virological failure than adults receiving ART. Interventions are needed to help improve outcomes and retention in care in this unique population.
几乎没有证据比较青少年与其他年龄组之间的治疗效果,尤其是在资源有限的环境中。对南非豪登省城市地区(n = 5)和姆普马兰加省农村地区(n = 2)的七家艾滋病诊所的数据进行了回顾性分析。该分析比较了2004年4月至2010年8月期间开始接受标准一线抗逆转录病毒治疗(ART)的未接受过ART治疗的HIV阳性青少年(10 - 14岁)、年长青少年(15 - 19岁)、青年成年人(20 - 24岁)与成年人(≥25岁)。采用对数二项回归来估计在6个月或12个月时病毒载量未被抑制(≥400拷贝/毫升)或未实现充分CD4反应的相对风险(RR)。使用Cox比例风险模型估计年龄组对病毒学失败、死亡率和失访(LTFU;自预定就诊日期起≥90天)的影响。在42427名开始接受ART治疗的患者中,310名(0.7%)是青少年,342名(0.8%)是年长青少年,1599名(3.8%)是青年成年人。青少年在男性比例、基线CD4计数、血红蛋白和结核病方面与成年人相似。与成年人相比,年长青少年(6个月RR 1.75,95%CI 1.25 - 2.47)和青年成年人(6个月RR 1.33,95%CI 1.10 - 1.60以及12个月RR 1.64,95%CI 1.23 - 2.19)更有可能病毒载量未被抑制,并且更有可能出现病毒学失败(HR 2.90,95%CI 1.74 - 4.86;HR 2.94,95%CI 1.63 - 5.31)。在那些死亡或失访的患者中,从开始接受ART治疗到死亡或失访的中位时间分别为4.7个月(IQR 1.5 - 13.2)和10.9个月(IQR 5.0 - 22.7)。与成年人相比,按年龄类别划分的死亡风险没有差异。青少年在开始接受ART治疗后的任何时间段内失访的可能性较小(HR 0.43,95%CI 0.26 - 0.69),而与成年人相比,年长青少年和青年成年人在开始接受ART治疗后失访的可能性更大(HR 1.78,95%CI 1.34 - 2.36;HR 1.63,95%CI 1.41 - 1.89)。与接受ART治疗的成年人相比,15至24岁的HIV感染青少年和青年成年人在病毒学反应、失访和病毒学失败方面ART治疗效果较差。需要采取干预措施来帮助改善这一特殊人群的治疗效果和治疗依从性。